416 related articles for article (PubMed ID: 28134850)
1. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.
Chua MM; Ortega CE; Sheikh A; Lee M; Abdul-Rassoul H; Hartshorn KL; Dominguez I
Pharmaceuticals (Basel); 2017 Jan; 10(1):. PubMed ID: 28134850
[TBL] [Abstract][Full Text] [Related]
2. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
[TBL] [Abstract][Full Text] [Related]
3. Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy.
McCarty MF; Assanga SI; Lujan LL
Med Hypotheses; 2020 Aug; 141():109723. PubMed ID: 32305811
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.
Gray GK; McFarland BC; Rowse AL; Gibson SA; Benveniste EN
Oncotarget; 2014 Aug; 5(15):6484-96. PubMed ID: 25153725
[TBL] [Abstract][Full Text] [Related]
5. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of CK2 in acute and chronic leukemias.
Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
[TBL] [Abstract][Full Text] [Related]
8. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
[TBL] [Abstract][Full Text] [Related]
10. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines.
Zhao T; Jia H; Li L; Zhang G; Zhao M; Cheng Q; Zheng J; Li D
Oncol Rep; 2013 Jul; 30(1):377-84. PubMed ID: 23595577
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase CK2 and Epstein-Barr Virus.
Montenarh M; Grässer FA; Götz C
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830895
[TBL] [Abstract][Full Text] [Related]
13. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
14. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
Liu S; Hsieh D; Yang YL; Xu Z; Peto C; Jablons DM; You L
BMC Pharmacol Toxicol; 2013 Jul; 14():36. PubMed ID: 23845105
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein kinase CK2 in the treatment of cholangiocarcinoma.
Jayaraman PS; Gaston K
Explor Target Antitumor Ther; 2021; 2(5):434-447. PubMed ID: 36045705
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase 2 (CK2): a potential regulator of immune cell development and function in cancer.
Husain K; Williamson TT; Nelson N; Ghansah T
Immunol Med; 2021 Sep; 44(3):159-174. PubMed ID: 33164702
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia.
Klink M; Rahman MA; Song C; Dhanyamraju PK; Ehudin M; Ding Y; Steffens S; Bhadauria P; Iyer S; Aliaga C; Desai D; Huang S; Claxton D; Sharma A; Gowda C
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807974
[TBL] [Abstract][Full Text] [Related]
18. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
Huang M; Yang W; Zhu J; Mariño-Enríquez A; Zhu C; Chen J; Wu Y; Quan Y; Qiu H; Li X; Chai L; Fletcher JA; Ou WB
Br J Cancer; 2020 Feb; 122(3):372-381. PubMed ID: 31776458
[TBL] [Abstract][Full Text] [Related]
19. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
20. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
